Search

Displaying results 441 - 450 of 8515 in total
  1. Drug

    Dienogest

    go.drugbank.com/drugs/DB09123
    ApprovedInvestigational

    Dienogest is commonly marketed as Visanne, Natazia and Qlaira. … It is a derivative of 19-nortestosterone and has antiandrogenic properties.

  2. Drug

    Dabrafenib

    go.drugbank.com/drugs/DB08912
    ApprovedInvestigational

    It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation.[L41955] It was also used for metastatic non-small cell lung cancer with the same mutation. … [L41955] In May 2018, Tafinlar (dabrafenib), in combination with Mekinist ([DB08911]), was approved to treat anaplastic thyroid cancer caused by an abnormal BRAF V600E gene.[L41955]

  3. Indication

    Electrolyte imbalance

    go.drugbank.com/conditions/DBCOND0015850
    Drugs: Dipotassium phosphate · Magnesium chloride · Sodium phosphate, monobasic
    Synonyms: Fluid/electrolyte/acid-base, Disorders of fluid, electrolyte and acid-base balance
  4. Drug

    Peanut oil

    go.drugbank.com/drugs/DB13964
    ApprovedWithdrawn

    [A33169] Under the FDA, peanut oil is categorized as an approved inactive ingredient for its use in drug products. … [L2242] Under Health Canada, it is approved as an active ingredient in over-the-counter combination products.[L1113]

  5. Drug

    Levopropoxyphene

    go.drugbank.com/drugs/DB06793
    ApprovedWithdrawn

    It was sold as an antitussive, but it was removed from the market in the 70s.[T133] Levopropoxyphene was developed by Lilly and FDA approved on March 21st, 1962. … This drug presented different dosages and it was administered as a capsule or suspension.

  6. Drug

    Rocuronium

    go.drugbank.com/drugs/DB00728
    ApprovedInvestigational

    [Sugammadex] is a γ-cyclodextrin derivative that has been introduced as a novel agent to reverse the action of rocuronium. … The drug is associated with the risk of developing allergic reactions in some high-risk patients, such as those with asthma.

  7. Drug

    Etuvetidigene Autotemcel

    go.drugbank.com/drugs/DB17593
    ApprovedInvestigational

    [L54693] WAS is a rare X-linked disorder caused by a mutation in the gene encoding the WAS protein, leading to a compromised immune system. … [A274878] The WAS protein is expressed on non-erythroid hematopoietic cells and regulates the function of actin filaments in the cytoskeleton.[A274878]

    Synonyms: Autologous CD34+ cells transfected with lentiviral vector containing the human WAS cDNA (Telethon 003)
  8. Drug

    Ketotifen

    go.drugbank.com/drugs/DB00920
    ApprovedInvestigational

    It has a similar structure to some other first-generation antihistamines such as [cyproheptadine] and [azatadine]. … [A231204] Ketotifen was first developed in Switzerland in 1970 by Sandoz Pharmaceuticals and was initially marketed for the treatment of anaphylaxis.

  9. Drug

    Torasemide

    go.drugbank.com/drugs/DB00214
    ApprovedInvestigational

    [A174463] Structurally, it is a pyridine-sulfonylurea used as an antihypertensive agent.[A319] Torasemide was first approved for clinical use by the FDA in 1993.[L5257]

  10. Drug

    Carbamazepine

    go.drugbank.com/drugs/DB00564
    ApprovedInvestigational

    [L1335] Interestingly, carbamazepine was the first anticonvulsant used to treat individuals with bipolar disorder.[A180319] … It was initially approved by the FDA in 1965.[A180301] Aside from the above uses, this drug is also given to control the symptoms of bipolar 1.